Evidence map›Paper›PMID 34981438›Full record

ArticleJournal of neurovirology2022

Relationship of the balloon analog risk task to neurocognitive impairment differs by HIV serostatus and history of major depressive disorder.

Rowan Saloner, Erin E Morgan, Mariam A Hussain, David J Moore, Robert K Heaton, Mariana Cherner, Igor Grant, Jennifer E Iudicello, TMARC Group

Open access · hybridAbstract read
In one paragraph

Article in Journal of neurovirology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Rowan SalonerJoint Doctoral Program in Clinical Psychology, San Diego State University/University of California, San Diego, San Diego, CA, USA. rsaloner@ucsd.edu.ORCID 0000-0002-1351-6183
Erin E MorganDepartment of Psychiatry, HIV Neurobehavioral Research Program, University of California, San Diego, San Diego, CA, USA.
Mariam A HussainJoint Doctoral Program in Clinical Psychology, San Diego State University/University of California, San Diego, San Diego, CA, USA.
David J MooreDepartment of Psychiatry, HIV Neurobehavioral Research Program, University of California, San Diego, San Diego, CA, USA.
Robert K HeatonDepartment of Psychiatry, HIV Neurobehavioral Research Program, University of California, San Diego, San Diego, CA, USA.
Mariana ChernerDepartment of Psychiatry, HIV Neurobehavioral Research Program, University of California, San Diego, San Diego, CA, USA.
Igor GrantDepartment of Psychiatry, HIV Neurobehavioral Research Program, University of California, San Diego, San Diego, CA, USA.
Jennifer E IudicelloDepartment of Psychiatry, HIV Neurobehavioral Research Program, University of California, San Diego, San Diego, CA, USA.
TMARC Group
University of California San Diego · USSan Diego State University · USUniversity of California, San Francisco · US

Funding

STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAVID J MOORE · 2001 to 2026
$50.4M
Translational Methamphetamine AIDS Research Center (TMARC)P50DA026306 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GRANT, IGOR · 2009 to 2018
$33.9M
Training in Research on Addictions in Interdisciplinary NeuroAIDS (TRAIN)T32DA031098 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jennifer E Iudicello, DAVID J MOORE · 2011 to 2026
$4.6M
Identification of Biomarkers of CNS injury and resilience related to HIV-1 and MethamphetamineR01DA047879 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IUDICELLO, JENNIFER E, LETENDRE, SCOTT L · 2018 to 2022
$3.7M
Mentoring Clinical Researchers at the Intersection of NeuroHIV and Substance AbuseK24DA040550 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHERNER, MARIANA · 2015 to 2025
$1.8M
Biomarkers of Blood Brain Barrier Injury in Methamphetamine Use and HIV DiseaseK23DA037793 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IUDICELLO, JENNIFER E · 2014 to 2018
$915k
SuperAging in HIV-infected Adults: Biopsychosocial Predictors of Neurocognitive Aging TrajectoriesF31AG064989 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SALONER, ROWAN · 2019 to 2021
$118k
NIA NIH HHS F31 AG064989NIA NIH HHS F31AG064989NIDA NIH HHS K23 DA037793NIDA NIH HHS K23DA037793NIDA NIH HHS K24 DA040550NIDA NIH HHS P50 DA026306NIDA NIH HHS P50DA026306NIDA NIH HHS R01 DA047879NIDA NIH HHS T32 DA031098NIDA NIH HHS T32DA031098NIMH NIH HHS P30 MH062512
6 · The paper itself

Abstract

HIV and major depressive disorder (MDD) commonly co-occur and are both linked to greater risk-taking behavior, possibly due to neurocognitive impairment (NCI). The present study examined the concordance of the Balloon Analog Risk Task (BART), a gold standard measure of risk-taking propensity, with NCI and real-world sexual risk behaviors in PWH with comorbid MDD. Participants included 259 adults, stratified by HIV serostatus (HIV + /HIV -) and lifetime MDD (MDD + /MDD -), who completed neuropsychological testing, the BART, and sexual risk behavior questionnaires. Logistic regression, stratified by HIV serostatus, examined joint effects of MDD and BART (linear and quadratic) on NCI. Follow-up linear regressions examined sexual risk behavior and neurocognitive domain T-scores as correlates of the BART. NCI prevalence was lowest in HIV - /MDD - , but BART scores did not differ by HIV/MDD status. In the HIV + group, BART performance predicted NCI such that high and low BART scores related to greater odds of NCI, but only in dual-risk HIV + /MDD + individuals. HIV + /MDD + individuals with both low and high BART scores exhibited poorer learning and recall, whereas processing speed and executive function were only poor in low BART risk-taking HIV + /MDD + . Higher BART scores linearly related to higher sexual risk behaviors only in MDD + individuals, independent of HIV serostatus. Low and high risk-taking on the BART may reflect discrete neurocognitive profiles in HIV + /MDD + individuals, with differential implications for real-world sexual risk behavior. HIV and comorbid MDD may disturb corticostriatal circuits responsible for integrating affective and neurocognitive components of decision-making, thereby contributing to risk-averse and risk-taking phenotypes.

Indexed as

HIV InfectionsMajor Depressive DisorderCognitionExecutive FunctionHumansNeuropsychological TestsRisk-TakingCognitionDecision makingDepressionHIV-associated neurocognitive disordersHIV riskRisk-taking

Identifiers

PMID34981438
PMCPMC9187559
OpenAlexW4206664778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.